TP Therapeutics Announces Phase 1 Data of Ropotrectinib (TPX-0005) to be Presented at the Annual American Society of Clinical Oncology Meeting
SAN DIEGO--(BUSINESS WIRE)--May 17, 2018--TP Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing oncology therapies with a focus on addressing current drug resistance, announced today that the Phase 1 data from the ongoing TRIDENT-1 Study of Ropotrectinib (TPX-0005) has been accepted for poster presentation and discussion on June 4 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
The presentation is entitled “A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor Ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1)”.
The schedule for the poster display and discussion is as follows:
Poster Discussion Time: 6/4/2018, 3:00 PM-4:15 PM
Title: A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor Ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1) Abstract Number: 2513 Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics Location: S406 Discussant: Valentina Boni, MD, PhD, START Madrid CIOCC Hospital Universitario Sanchinarro
Poster Display Information: Monday, June 4, 2018, 8:00-11:30 am Location: Hall A Lead author: Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center
About Ropotrectinib (TPX-0005)
Ropotrectinib (TPX-0005) is a potent and orally bioavailable investigational small molecule kinase inhibitor for ALK, ROS1, and TRK family. The clinical benefits of targeting ALK, ROS1, or TRK fusion kinase have been demonstrated with multiple kinase inhibitors already approved for the treatment of ALK + non-small cell lung cancer (NSCLC), in addition to crizotinib for ROS1 + NSCLC, and larotrectinib and entrectinib in clinical studies for TRK + cancers. The successes of these therapies are overshadowed by the development of acquired resistance. The acquired solvent front mutations including ALK G1202R, ROS1 G2032R, TRKA G595R and TRKC G623R render a common clinical resistance to the current ALK, ROS1, and TRK inhibitors. TPX-0005 is a potent kinase inhibitor against wildtype and mutated ALK, ROS1 and TRK family kinases, especially the clinically significant solvent front mutations, gatekeeper mutations, and emerging compound mutations after multiple line treatments. Ropotrectinib may provide new opportunities in the clinic to inhibit the abnormal signaling of ALK, ROS1, or TRK family in solid malignancies, and overcome resistance seen in refractory patients. TPX-0005 is currently being evaluated in a Phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics and anti-tumor activity in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1, NCT03093116 ). For additional information about ropotrectinib trial, please refer to www.clinicaltrials.gov. Interested patients and physicians can also contact the TP Therapeutics Oncology Clinical Trial Hotline at 1-858-276-0005 or email email@example.com.
About TP Therapeutics, Inc.
TP Therapeutics, Inc. (TP) is a clinical-stage structure-based oncology drug design company founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib. The TP team is focused on the design and development of novel chemical entities within oncology for established oncogene drivers with high incidence of secondary resistance mutations; newly identified disease-driven targets; and potential targets regulating tumor microenvironment and tumor immunity. For more information, please visit us at www.tptherapeutics.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180517005008/en/
CONTACT: TP Therapeutics, Inc.
Y. Peter Li, Ph.D., M.B.A.
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA ILLINOIS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: TP Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 05/17/2018 07:00 AM/DISC: 05/17/2018 07:01 AM